REFERENCES

1. Khalil H, Arfa M, El-Masrey S, EL-Sherbini S, Abd-Elaziz A. Single nucleotide polymorphisms of interleukins associated with hepatitis C virus infection in Egypt. J Infect Dev Ctries 2017;11:261-8.

2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.

3. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology. Medizin Fokus Verlag 2016;1:197-207.

4. Pirakitikulr N, Kohlway A, Lindenbach BD, Pyle AM. The coding region of the HCV genome contains a network of regulatory RNA structures. Mol Cell 2016;62:111-20.

5. Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr Opin Virol 2012;2:14-9.

6. Douam F, Lavillette D, Cosset FL. The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci 2015;129:63-107.

7. Eyre NS, Drummer HE, Beard MR. The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog 2010;6:e1001130.

8. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-5.

9. Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 2007;81:588-98.

10. Samreen B, Khaliq S, Ashfaq UA, Khan M, Afzal N, Shahzad MA, Riaz S, Jahan S. Hepatitis C virus entry: Role of host and viral factors. Infect Genet Evol 2012;12:1699-709.

11. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-9.

12. Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag 2014;10:493-504.

13. Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K; Polish Group of Experts for HCV,. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol 2017;3:47-55.

14. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, Elledge SJ. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 2009;106:16410-5.

15. Brenner BG, Wainberg Z. Heat shock proteins: novel therapeutic tools for HIV-infection? Expert Opin Biol Ther 2001;1:67-77.

16. Santoro MG. Heat shock proteins and virus replication: hsp70s as mediators of the antiviral effects of prostaglandins. Experientia 1994;50:1039-47.

17. Braga ACS, Carneiro BM, Batista MN, Akinaga MM, Bittar C, Rahal P. Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity. PLoS One 2017;12:e0188467.

18. Brenu EW, Staines DR, Tajouri L, Huth T, Ashton KJ, Marshall-Gradisnik SM. Heat shock proteins and regulatory T cells. Autoimmune Dis 2013;2013:813256.

19. Pandey R, Mandal AK, Jha V, Mukerji M. Heat shock factor binding in Alu repeats expands its involvement in stress through an antisense mechanism. Genome Biol 2011;12:R117.

20. Häsler J, Strub K. Alu elements as regulators of gene expression. Nucleic Acids Res 2006;34:5491-7.

21. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet 2002;3:370-9.

22. Wilson DN, Nierhaus KH. Ribosomal proteins in the spotlight. Crit Rev Biochem Mol Biol 2005;40:243-67.

23. Warner JR, McIntosh KB. How common are extraribosomal functions of ribosomal proteins? Mol Cell 2009;34:3-11.

24. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol 2013;19:17-25.

25. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, Bader el-Din NG, Redwan el-RM, el-Demellawy M, Omran MH, el-Garf WT, Goueli SA. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006;12:4836-42.

26. Khalil H, El Malah T, El Maksoud AIA, El Halfawy I, El Rashedy AA, El Hefnawy M. Identification of novel and efficacious chemical compounds that disturb influenza a virus entry in vitro. Front Cell Infect Microbiol 2017;7:304.

27. Khalil H. Influenza A virus stimulates autophagy to undermine host cell IFN-β production. Egypt J Biochem Mol Biol 2012;30:283-99.

28. Khalil H, Tazi M, Caution K, Ahmed A, Kanneganti A, Assani K, Kopp B, Marsh C, Dakhlallah D, Amer AO. Aging is associated with hypermethylation of autophagy genes in macrophages. Epigenetics 2016;11:381-8.

29. Mann M, Wright PR, Backofen R. IntaRNA 2.0: enhanced and customizable prediction of RNA-RNA interactions. Nucleic Acids Res 2017;45:W435-9.

30. Wright PR, Georg J, Mann M, Sorescu DA, Richter AS, Lott S, Kleinkauf R, Hess WR, Backofen R. CopraRNA and IntaRNA: predicting small RNA targets, networks and interaction domains. Nucleic Acids Res 2014;42:W119-23.

31. Busch A, Richter AS, Backofen R. IntaRNA: efficient prediction of bacterial sRNA targets incorporating target site accessibility and seed regions. Bioinformatics 2008;24:2849-56.

32. Schmittgen TD, Jiang J, Liu Q, Yang L. A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 2004;32:e43.

33. Di Ruocco F, Basso V, Rivoire M, Mehlen P, Ambati J, De Falco S, Tarallo V. Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. Oncogene 2018;37:627-37.

34. Häsler J, Samuelsson T, Strub K. Useful "junk": Alu RNAs in the human transcriptome. Cell Mol Life Sci 2007;64:1793-800.

35. Shamovsky I, Ivannikov M, Kandel ES, Gershon D, Nudler E. RNA-mediated response to heat shock in mammalian cells. Nature 2006;440:556-60.

36. Novetsky AP, Zighelboim I, Thompson DM, Powell MA, Mutch DG, Goodfellow PJ. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol 2013;128:470-4.

37. Fahl SP, Harris B, Coffey F, Wiest DL. Rpl22 loss impairs the development of B lymphocytes by activating a p53-dependent checkpoint. J Immunol 2015;194:200-9.

38. Wood J, Frederickson RM, Fields S, Patel AH. Hepatitis C virus 3'X region interacts with human ribosomal proteins. J Virol 2001;75:1348-58.

39. Huang L, Hwang J, Sharma SD, Hargittai MRS, Chen Y, Arnold JJ, Raney KD, Cameron CE. Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem 2005;280:36417-28.

40. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52.

41. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011;85:7312-20.

42. He Y, Staschke KA, Tan S. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. pp. 267-92.